Table 1 Baseline characteristics of the short and long duration groups before and after weighting.

From: Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma

Characteristic

Unweighted, N%

Weighted, N%

Short duration

Long duration

p value

Short duration

Long duration

p value

SMD

n = 128

n = 128

  

Sex

  

0.69

  

0.82

0.03

 Female

42(33)

45(35)

 

(31)

(33)

  

 Male

86(67)

83(65)

 

(69)

(67)

  

Age

  

0.06

  

0.96

0.007

 <45 years

53(41)

68(53)

 

(46)

(46)

  

 ≥45 years

75(59)

60(47)

 

(54)

(54)

  

Family history of NPC

  

0.18

  

0.89

0.02

 No

120(94)

114(89)

 

(91)

(91)

  

 Yes

8(6)

14(11)

 

(9)

(9)

  

T categorya

  

0.03

  

0.96

0.008

 T1-2

5(4)

14(11)

 

(8)

(8)

  

 T3-4

123(96)

114(89)

 

(92)

(92)

  

N categorya

  

0.90

  

0.95

0.008

 N0-1

46(36)

45(35)

 

(35)

(35)

  

 N2-3

82(64)

83(65)

 

(65)

(65)

  

Overall stagea

  

0.02

  

0.89

0.02

 III

60(47)

41(32)

 

(40)

(39)

  

 IVa

68(53)

87(68)

 

(60)

(61)

  

Schemes

  

<0.001

  

0.96

0.007

 CCRT + AC

67(52)

34(27)

 

(40)

(40)

  

 IC + CCRT + AC

61(48)

94(73)

 

(60)

(60)

  

Pretreatment EBV DNA

  

0.90

  

0.85

0.03

 ≤4000 copies/mL

79(62)

78(61)

 

(61)

(63)

  

 >4000 copies/mL

49(38)

50(39)

 

(39)

(37)

  
  1. The chi-squared test was used to calculate p value. All variables were transformed into categorical variables.
  2. SMD standardised mean difference, NPC nasopharyngeal carcinoma, CCRT concurrent chemoradiotherapy, AC adjuvant chemotherapy, IC induction chemotherapy, EBV Epstein–Barr virus.
  3. aAccording to the eighth edition of UICC/AJCC staging system.
Back to article page